PD-1 Inhibitors Prolong Survival in Leptomeningeal Disease

Abstract According to interim results of a phase I trial, patients with melanoma and leptomeningeal disease who received intrathecal and intravenous nivolumab, a PD-1 inhibitor, experienced a median overall survival of 4.9 months compared with a historical average of about 6 weeks with radiation and chemotherapy. No dose-limiting toxicities were reported.